Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:16 PM
Ignite Modification Date:
2026-03-26 @ 3:16 PM
NCT ID:
NCT07408804
Eligibility Criteria:
Inclusion Criteria:
1. Age 18-75 years,
2. Hepatocellular carcinoma, confirmed by dynamic CT scan / MRI or histopathology, consistent with early (stage A), Intermediate (Stage B), subgroup B, and Advanced (stage C) according to BCLC criteria 2022, without a history of any previous treatment,
3. At least one measurable lesion based on mRECIST criteria,
4. ECOG performance status 0-2,
Exclusion Criteria:
1. Diffuse bi-lobar or multi nodular HCC (more than 10 nodules) with more than equal 50% liver involvement,
2. Hepatocellular carcinoma with main trunk portal vein thrombosis,
3. Child Turcotte Pugh Score 10 ( C) or more,
4. ALBI grade 3,
5. Hepatocellular carcinoma with uncontrolled hypertension, recent myocardial infarction, or other thromboembolic event,
6. Known allergy or intolerance to lenvatinib .
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT07408804
Study Brief:
Protocol Section:
NCT07408804